<< Lawmakers hope to combine Senate, House health reform bills quickly | Disability-related problems continue to rise among older adults >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Baylor University Medical Center adds Naviscan PEM to its imaging services

Published on December 22, 2009 at 10:58 AM · No Comments

The Baylor University Medical Center in Dallas has taken delivery of the Naviscan PEM scanner at its Darlene G. Cass Women's Imaging Center. Baylor will utilize PEM (Positron Emission Mammography) to complement their existing anatomical tools by providing a critical three-dimensional metabolic perspective of breast cancer. The metabolic view allows physicians to make the optimal cancer care decisions by providing an unprecedented ability to distinguish between benign and malignant lesions in what researchers call "specificity". A recent multi-center NIH-sponsored study comparing PEM and MRI highlighted that PEM had improved specificity relative to MRI at comparable sensitivity, what researchers use to describe the ability to see lesions.

The Darlene G. Cass Women's Imaging Center has been a leader in breast imaging services in the Dallas area for more than 20 years, performing more than 50,000 breast imaging procedures annually. The Women's Imaging Center, which is fully accredited in mammography, stereotactic breast biopsy, breast ultrasound and ultrasound-guided breast biopsy, now adds PEM to its imaging services.

"We recently received prestigious designation as one of five 'Top Women's Imaging Centers to Watch in 2009' from Imaging Technology News acknowledging our commitment to providing the highest level of breast care to our patients," said Zeeshan Shah, M.D., at Baylor University. "Our leading technology, radiology expertise and our dedication to the detection of breast cancer has allowed us to provide exquisite care to thousands of women. Our expectation is that PEM will prove indispensable to effective breast cancer management for both our referring physicians and our patient population."

SOURCE Naviscan, Inc.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading